Connecticut 500 W Putnam Ave Ste 435 Greenwich, CT 06830





OCREVUS ZUNOVOTM

(ocrelizumab and hyaluronidase-ocsq) Date:				
	PATIENT	INFORMATI	ON	
Name:	Phone:		DOB:	SEX: M □ F □
□NKDA Allergies:		Weight lbs/kg:		
	PHYSICIA	N INFORMAT	ΓΙΟΝ	
Physician Name:	11115161/1	Practice Name:		
Address:		Office Contact N	Name:	Office Contact #:
Phone: Fax:		Email (for updates):		
REFERRAL STATUS				
□New Referral □Referral Renewal	□Medication/Order C	Thange □Benefit	s Verification Only	□Discontinuation Order
• Relapsing forms of multiple sclerosis (MS), to progressive disease, in adults (1) • Primary progressive MS, in adults (1)		•		tive secondary
□ ICD-10*:		WARNINGS AND PRECAUTIONS hhttps://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf		
PRE-MEDICATION Tylenol PO 650mg □1000mg □other		PATIENT WEIGHT lbs kg DOSAGE: Injection 920mg per 23ml (40 mg vial FREQQUENCY: Every 6 months	g ocrelizumab and 23, g and 1,000 units/mL) for mont	000 units of hyaluronidase solution in a single-dose th
NOTES/ADDITIONAL COMMENTS:		REQUIRED DOO	CUMENTATION C	HECKLIST:
	Patient Demographics Insurance Card/Information Recent labs to include Hepatitis Panel and CBC, as well as CMP and quantitative, if available *Please send any other recent labs Recent Progress note and MRI of Brain Other			
ORDERING PROVIDER		_		
Signature X		Pate	•	
Provider	DI F		Order/dosage: Signature:	